Kisspeptin-54

Mechanism

The full-length version of kisspeptin, a hormone that acts as the master switch for reproduction. While kisspeptin-10 (a shorter fragment) is already used in research, the full 54-amino-acid version lasts longer and produces a more sustained stimulation of reproductive hormones. It is being studied as a safer alternative to hCG for triggering egg maturation during IVF, since it carries a much lower risk of ovarian hyperstimulation syndrome (OHSS).

Effects

ENDOCRINE SYSTEM (REPRODUCTIVE AXIS): Kisspeptin-54 (full-length metastin) is the 54-amino-acid product of the KISS1 gene and the most potent endogenous activator of GnRH neurons via the KISS1R (GPR54) receptor [in vitro, animal, clinical]. Stimulates pulsatile GnRH release from the hypothalamus, driving LH and FSH secretion from the pituitary — this is the physiological "master switch" of the reproductive axis [clinical — Dhillo et al., 2005, 2007]. IVF OOCYTE MATURATION TRIGGER: When administered as a single subcutaneous injection (1.6-12.8 nmol/kg), kisspeptin-54 triggers an endogenous LH surge sufficient for oocyte maturation — a physiological alternative to hCG or GnRH agonist triggers [RCT — Abbara et al., 2015, 2017]. OHSS RISK REDUCTION: The key clinical advantage — kisspeptin-54 trigger produces a shorter-duration, lower-amplitude LH surge compared to hCG, significantly reducing ovarian hyperstimulation syndrome (OHSS) risk [RCT]. In high-risk patients (PCOS, high AMH, high antral follicle count), kisspeptin trigger virtually eliminates severe OHSS while maintaining acceptable oocyte yield and pregnancy rates [RCT — Abbara et al., 2020]. Mechanism: kisspeptin-induced LH surge lasts ~12-18 hours (vs. hCG's 5-7 day sustained luteotropic effect), causing less vascular endothelial permeability and fluid shifts [clinical, pharmacokinetic]. COMPARISON TO KISSPEPTIN-10: Kisspeptin-54 has longer duration of action and greater LH area-under-curve than kisspeptin-10 (the shorter C-terminal fragment), due to slower enzymatic degradation and different receptor binding kinetics [clinical comparison]. Kisspeptin-10 produces a briefer LH pulse — useful for research but less reliable for IVF triggering. NEUROENDOCRINE EFFECTS: Kisspeptin-54 also stimulates GH, prolactin, TSH, and ACTH secretion, though reproductive axis effects dominate clinically [clinical studies]. Modulates appetite and metabolic signaling via hypothalamic integration with energy balance pathways [animal, clinical]. PSYCHOLOGICAL: Kisspeptin administration enhances limbic brain activity in response to sexual and romantic stimuli (fMRI studies) — potential role in hypoactive sexual desire [RCT — Comninos et al., 2017].

Practitioner Guide

ADMINISTRATION: Subcutaneous injection. Currently available only through specialized IVF research centers — primarily Imperial College London and affiliated programs. Not yet commercially available or FDA/EMA-approved for IVF triggering (as of early 2026). DOSING FOR IVF TRIGGER: Single subcutaneous injection of 9.6 nmol/kg (the dose used in most Phase II trials) administered when lead follicles reach ≥18 mm and ≥3 follicles ≥17 mm. Oocyte retrieval 36 hours post-injection (same timing as hCG trigger). Higher doses (12.8 nmol/kg) may produce more consistent LH surges across patients but data is still maturing. PATIENT SELECTION: Ideal candidates for kisspeptin trigger: PCOS patients undergoing IVF, patients with previous OHSS, patients with AMH >35 pmol/L or antral follicle count >20, any patient at high risk for OHSS. NOT recommended for poor responders (need robust LH surge, and kisspeptin's physiological surge may be insufficient for suboptimal follicular cohorts). LUTEAL SUPPORT: Because kisspeptin trigger does not provide sustained luteotropic support (unlike hCG), aggressive luteal phase support is essential — progesterone supplementation (vaginal, IM, or SC) starting the day after retrieval. Some protocols add a single low-dose hCG bolus (1500 IU) post-retrieval for luteal rescue without triggering OHSS. Fresh embryo transfer is feasible with adequate luteal support, though freeze-all with deferred transfer remains an option. COMPARISON TO GnRH AGONIST TRIGGER: GnRH agonist trigger (e.g., leuprolide 1 mg SC) also reduces OHSS risk but produces a dual LH + FSH flare. Kisspeptin trigger may be preferable because: (1) it works even in patients who have been down-regulated with GnRH antagonist protocols (GnRH agonist trigger requires intact pituitary GnRH receptors), (2) the LH surge profile may be more physiological. Both approaches require robust luteal support. RESEARCH vs. CLINICAL USE: Kisspeptin-54 IVF triggering is currently a research protocol, not standard of care. Practitioners interested in this approach should refer patients to participating trial centers or await regulatory approval. STORAGE: Research-grade kisspeptin-54 is lyophilized and stored at -20°C. Reconstituted in sterile water or saline for injection.

Evidence

• Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy

  Abbara A et al. (2015) — J Clin Endocrinol Metab — PMID: 26192876

  In 60 women at high risk of OHSS undergoing IVF, single-dose kisspeptin-54 triggered oocyte maturation in 95% of participants, produced live birth rates up to 62% per transfer at the best-performing dose, and no woman developed moderate, severe, or critical OHSS.

  moderate

Research Summary

TIER 1: Phase II RCTs from Imperial College London (Abbara et al., 2015, 2017, 2020) — kisspeptin-54 trigger in IVF patients: effective oocyte maturation with near-elimination of moderate/severe OHSS in high-risk groups. Oocyte maturity rates 79-90% (comparable to hCG in optimized protocols). Live birth rate data accumulating — early results promising. Dhillo et al., 2005, 2007 — foundational human studies demonstrating kisspeptin-54 stimulates gonadotropin release in healthy volunteers. Comninos et al., 2017 — RCT showing kisspeptin enhances limbic brain responses to sexual stimuli. No FDA/EMA approval yet — Phase III trials anticipated. TIER 2: Systematic reviews of kisspeptin physiology and reproductive endocrinology (Skorupskaite et al., 2014; Abbara et al., review publications). Comparative pharmacology studies of kisspeptin-54 vs. kisspeptin-10 in human volunteers. Dose-finding studies establishing optimal IVF trigger dose (9.6-12.8 nmol/kg range). Mechanistic studies on OHSS pathophysiology and why kisspeptin is protective. Reviews of kisspeptin's role in puberty, fertility, and metabolic integration. TIER 3: Case series from Imperial College IVF program. Expert opinion and review articles positioning kisspeptin as the future of OHSS-free IVF. International reproductive endocrinology meeting abstracts. Preclinical studies on kisspeptin analogs with improved stability. KEY FINDINGS: Kisspeptin-54 is arguably the most exciting development in IVF pharmacology in the past decade — it offers a physiological oocyte maturation trigger that largely eliminates OHSS, the most dangerous complication of IVF. The data is strong and growing. The limitation is the current lack of regulatory approval and restricted availability. The research is concentrated at Imperial College London (Dhillo/Abbara group). GAPS: Phase III RCTs not yet completed. Long-term offspring safety data not available. Optimal dosing protocol still being refined. Commercial manufacturing and regulatory pathway uncertain. Limited independent replication outside Imperial College. ACTIVE TRIALS: Phase II/III trials ongoing at Imperial College Healthcare NHS Trust. Multi-center studies anticipated. Research into kisspeptin analogs with improved pharmacokinetics.